Monday, May 12, 2014

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

This meta-analysis found that zanamivir, an antiviral neuraminidase inhibitor, reduced the time to symptomatic improvement in adults (but not children) with influenza. Adults treated with zanamivir had symptom relief about 12 hours earlier than adults not treated with zanamivir. The authors found NO evidence that zanamivir reduced the risk of influenza complications such as pneumonia, hospital admissions, or death. Side effects were minor except for bronchospasm. Use for prophylaxis was not found to be of significant benefit.
Read More